Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:AVIRNASDAQ:AVTENASDAQ:NGNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.07+5.9%$1.08$0.86▼$3.92$64.81M0.09291,267 shs165,356 shsAVIRAtea Pharmaceuticals$2.74+5.8%$2.91$2.46▼$4.15$234.49M0.17306,915 shs528,557 shsAVTEAerovate Therapeutics$7.40-2.0%$67.46$43.75▼$884.98$214.49M0.9518,345 shs271,381 shsNGNENeurogene$17.99-7.1%$13.49$6.88▼$74.49$256.57M1.56240,829 shs313,262 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals+5.94%+9.17%+9.18%-26.21%-71.84%AVIRAtea Pharmaceuticals+5.79%+0.74%-8.67%-13.02%-26.15%AVTEAerovate Therapeutics-1.99%-17.78%-92.11%-91.37%-98.99%NGNENeurogene-7.12%+23.22%+67.04%-2.33%-46.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.7292 of 5 stars3.73.00.00.02.61.70.6AVIRAtea Pharmaceuticals2.547 of 5 stars3.32.00.00.02.12.51.3AVTEAerovate Therapeutics1.5877 of 5 stars3.00.00.00.03.51.70.6NGNENeurogene2.1023 of 5 stars3.50.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.33Buy$7.33585.36% UpsideAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.00118.98% UpsideAVTEAerovate Therapeutics 2.00Hold$78.75964.19% UpsideNGNENeurogene 3.00Buy$43.40141.25% UpsideCurrent Analyst Ratings BreakdownLatest ABOS, AVIR, NGNE, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$38.00 ➝ $24.005/13/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.004/14/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $16.004/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.003/28/2025ABOSAcumen PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/28/2025ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $11.003/25/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$38.003/25/2025NGNENeurogeneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/25/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $50.003/7/2025AVIRAtea PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/A$6.65 per shareN/AAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ANGNENeurogene$925K277.38N/AN/A$14.51 per share1.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.94N/AN/AN/AN/A-32.99%-27.99%N/AAVIRAtea Pharmaceuticals-$135.96M-$1.65N/AN/AN/AN/A-34.90%-32.38%N/AAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/ANGNENeurogene-$36.32M-$4.35N/AN/AN/AN/A-32.81%-27.96%N/ALatest ABOS, AVIR, NGNE, and AVTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/A5/9/2025Q1 2025NGNENeurogene-$1.05-$1.08-$0.03-$1.08N/AN/A4/25/2025Q4 2024AVTEAerovate Therapeutics-$10.50-$3.15+$7.35-$0.09N/AN/A3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/A3/27/2025Q4 2024AVTEAerovate Therapeutics-$6.65-$6.65N/A-$0.19N/AN/A3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 million3/6/2025Q4 2024AVIRAtea Pharmaceuticals-$0.35-$0.40-$0.05-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ALatest ABOS, AVIR, NGNE, and AVTE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/9/2025AVTEAerovate Therapeutics$84.004/29/20254/25/20254/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1410.4310.43AVIRAtea PharmaceuticalsN/A19.3319.33AVTEAerovate TherapeuticsN/A8.788.78NGNENeurogeneN/A9.099.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%AVIRAtea Pharmaceuticals86.67%AVTEAerovate TherapeuticsN/ANGNENeurogene52.37%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%AVIRAtea Pharmaceuticals18.10%AVTEAerovate Therapeutics24.90%NGNENeurogene11.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million55.81 millionOptionableAVIRAtea Pharmaceuticals7085.58 million69.43 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableNGNENeurogene9014.26 million13.38 millionOptionableABOS, AVIR, NGNE, and AVTE HeadlinesRecent News About These CompaniesBaird Downgrades Neurogene (NGNE)May 16 at 9:45 PM | msn.comNeurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAVMay 16 at 4:45 PM | finance.yahoo.comStuart Cobb Sells 6,797 Shares of Neurogene Inc. (NASDAQ:NGNE) StockMay 16 at 9:23 AM | insidertrades.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $748,000 Position in Neurogene Inc. (NASDAQ:NGNE)May 16 at 6:26 AM | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Buy" by AnalystsMay 16 at 4:49 AM | marketbeat.comSchonfeld Strategic Advisors LLC Sells 23,477 Shares of Neurogene Inc. (NASDAQ:NGNE)May 16 at 3:48 AM | marketbeat.comWhat is HC Wainwright's Forecast for Neurogene Q2 Earnings?May 16 at 1:56 AM | americanbankingnews.comNeurogene (NASDAQ:NGNE) Given New $45.00 Price Target at HC WainwrightMay 15 at 8:19 AM | marketbeat.comOctagon Capital Advisors LP Increases Stake in Neurogene Inc. (NASDAQ:NGNE)May 15 at 7:42 AM | marketbeat.comDriehaus Capital Management LLC Sells 69,422 Shares of Neurogene Inc. (NASDAQ:NGNE)May 13, 2025 | marketbeat.comNeurogene (NASDAQ:NGNE) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPSMay 13, 2025 | marketbeat.comDAFNA Capital Management LLC Has $1.18 Million Position in Neurogene Inc. (NASDAQ:NGNE)May 10, 2025 | marketbeat.comDeerfield Management Company L.P. Series C Makes New Investment in Neurogene Inc. (NASDAQ:NGNE)May 10, 2025 | marketbeat.comNeurogene Reports First Quarter 2025 Financial Results and Highlights Recent UpdatesMay 9, 2025 | businesswire.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2025 | businesswire.comCasdin Capital LLC Grows Stake in Neurogene Inc. (NASDAQ:NGNE)May 8, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Invests $2.82 Million in Neurogene Inc. (NASDAQ:NGNE)May 8, 2025 | marketbeat.comNeurogene (NGNE) Expected to Announce Quarterly Earnings on FridayMay 8, 2025 | americanbankingnews.comBaker BROS. Advisors LP Boosts Holdings in Neurogene Inc. (NASDAQ:NGNE)May 6, 2025 | marketbeat.comArrowMark Colorado Holdings LLC Has $10.26 Million Stock Position in Neurogene Inc. (NASDAQ:NGNE)May 6, 2025 | marketbeat.comNeurogene (NGNE) Expected to Announce Earnings on FridayMay 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABOS, AVIR, NGNE, and AVTE Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.07 +0.06 (+5.94%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.02 -0.05 (-4.21%) As of 05/16/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Atea Pharmaceuticals NASDAQ:AVIR$2.74 +0.15 (+5.79%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$2.74 0.00 (0.00%) As of 05/16/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Aerovate Therapeutics NASDAQ:AVTE$7.40 -0.15 (-1.99%) As of 05/15/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Neurogene NASDAQ:NGNE$17.99 -1.38 (-7.12%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$17.70 -0.29 (-1.61%) As of 05/16/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
